This order has been set on revision status. Please press the "Confirm" button to tell us you are aware of this, and that you will complete it within the time provided.

Cytokine 98 (2017) 51–58

Contents lists available at ScienceDirect

Cytokine

journal homepage: www.journals.elsevier.com/cytokine

Review article

Leptin in inflammation and autoimmunity

http://dx.doi.org/10.1016/j.cyto.2016.10.011 1043-4666/� 2016 Elsevier Ltd. All rights reserved.

E-mail address: [email protected]

Antonio La Cava Department of Medicine, University of California Los Angeles, 1000 Veteran Ave. 32-59, Los Angeles, CA 90095, United States

a r t i c l e i n f o a b s t r a c t

Article history: Received 1 September 2016 Received in revised form 18 October 2016 Accepted 19 October 2016

Keywords: Leptin Inflammation Autoimmunity

After its discovery as a key controller of metabolic function, leptin has been later extensively implicated in additional functions including important modulatory activities on the innate and adaptive immune response. This review analyzes the known implications of leptin in multiple inflammatory conditions, including autoimmune diseases, and how this knowledge could be instrumental in the design of leptin-based manipulation strategies to help restoration of abnormal immune responses.

� 2016 Elsevier Ltd. All rights reserved.

Contents

1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51 2. Immune effects of leptin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52

2.1. Leptin signaling in immune cells . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52

3. Leptin in non-autoimmune inflammation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53

3.1. Leptin and atherosclerosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53 3.2. Leptin and type 2 diabetes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 3.3. Renal inflammation. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 3.4. Chronic obstructive pulmonary disease (COPD) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 3.5. Behçet’s disease. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 3.6. Pelvic endometriosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 3.7. Leptin and cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 3.8. Leptin and infection . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54

4. Leptin and autoimmunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54

4.1. Leptin and type-1 diabetes (T1D). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 4.2. Leptin and multiple sclerosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 4.3. Leptin and inflammatory bowel disease (IBD) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 4.4. Leptin and autoimmune arthritis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 4.5. Leptin and systemic lupus erythematosus. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 4.6. Leptin in psoriasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55

5. Conclusions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 Funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55 References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 55

1. Introduction

Leptin is a 16 kDa non-glycosylated protein that is mainly pro- duced by adipocytes, for which reason it belongs to the group of

cytokines that are commonly called adipocytokines or adipokines [1]. Leptin has a dual role as a hormone and a cytokine. As hormone, it influences multiple endocrine functions and bone metabolism, in addition to the key function of modulating energy homeostasis through mechanisms that include thermoregulation. As a cytokine, leptin promotes inflammatory responses. It derives

52 A. La Cava / Cytokine 98 (2017) 51–58

that elevated levels of circulating leptin in obese patients con- tribute significantly to the low-grade inflammatory state that makes those individuals more susceptible to develop cardiovascu- lar diseases, type II diabetes, or degenerative disease [2], in addi- tion to autoimmune disease [3]. Conversely, reduced levels of leptin such as those found in malnourished individuals have been linked to increased risk of infection and reduced cell-mediated immunity [3], likely secondarily to an insufficient immune cell effector activity that cannot allow a proper control of pathogens (possibly concomitantly with an enhanced function of CD4+ regu- latory T cells (Tregs) that suppress effector immune responses) [4]. These data point to the fact that leptin, together with its role in the regulation of food intake and energy expenditure [5], also exerts a strong proinflammatory activity likely linked to its resem- blance to IL-6 [6].

Leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice not only have metabolic abnormalities and morbid obesity but also a series of marked abnormalities in neuroendocrine func- tions, angiogenesis, reproduction, insulin secretion, wound healing, hematopoiesis and lymphopoiesis, suggesting an involvement of leptin in the regulation of multiple important physiologic functions [7]. In addition to those disturbances, genetic deficiency in the lep- tin axis in both mice and humans associates with thymus atrophy and immune deficiency, in addition to an increased susceptibility to opportunistic infection [8,9]. Importantly, the impaired T-cell proliferation, reduced number of circulating CD4+ T cells (particu- larly naïve T cells) and impaired cytokine production (lack of IFN-c secretion and reduced IL-4 and IL-10 production) present in leptin- deficient subjects can all be reversed by the administration of recombinant leptin, demonstrating an important role of leptin on the physiology of the immune response [7].

2. Immune effects of leptin

Innate immune responses and inflammation are interwoven processes. As a first line of defense against infection, innate immu- nity operates to fight against pathogens to which it had no prior exposure. However, this limited lack of specificity in the effector immune response can lead to the production of inflammatory mediators that may harm the host, particularly if the response is prolonged or insufficiently controlled by the host’s homeostatic mechanisms. The activation of innate immune cells including poly- morphonuclear leukocytes (PMN) such as neutrophils, eosinophils, and basophils induced by proinflammatory insults favors the migration of these cells towards chemotactic stimuli produced at sites of inflammation. Once there, these cells produce powerful local mediators that cause harm to the pathogen but at the mean- time can damage the host tissue. Together with the soluble medi- ators released by innate immune cells, macrophage phagocytosis, and dendritic cell (DC) presentation of antigens derived from the pathogen, adaptive immune responses ensue, with the recruitment of B and T lymphocytes. It derives that longer timeframes are required to mount an adaptive immune response (yet character- ized by higher specificity and great efficacy also for the possibility to generate long-lasting immune responses available in case of subsequent encounters with the same pathogen). Interestingly, leptin provides a contribution to both the innate and adaptive immune response. Specifically, in monocytes/macrophages, leptin stimulates the expression of CD39, CD69, CD25, CD71 and IL-1Ra [10], and the production of proinflammatory cytokines IL-6 and TNF-a [11]. Moreover, it favors proliferation, phagocytosis through phospholipase activation [10], and the production of eicosanoids, nitric oxide, leukotriene B4 (LTB4) and cyclooxygenase 2 (COX-2) from these cells [12,13]. In neutrophils, leptin promotes chemotaxis and the release of reactive oxygen species [14]. It also

protects neutrophils from apoptosis involving PI3K- and MAPK- dependent pathways, delays cleavage of Bid and Bax and mito- chondrial release of cytochrome c and the activation of caspases [15], and upregulates the expression of several adhesion molecules and chemotaxis induced by the eosinophil chemoattractant RANTES [16].

In NK cells, leptin contributes to cell development, proliferation and cytotoxicity (this last function occurs via an upregulation of IL- 2 and perforin expression through activation of STAT3) [17]. In DC, leptin promotes maturation and survival [18].

In general, leptin has proinflammatory properties and activities similar to other acute phase reactants, and upregulates the secre- tion of multiple inflammatory cytokines including TNF-a, IL-6, and IL-12 [6]. Moreover, after exposure to inflammatory stimuli such as LPS, TNF-a, and IL-1, the levels of circulating leptin and leptin expression in the adipose tissue increase [19,20]. Conversely, TNF-a and IL-1b increase the expression of leptin mRNA in the adi- pose tissue, creating a loop whose components influence each other in promoting inflammation [20]. Thus, proinflammatory mediators such as TNF-a and IL-1 - which upregulate leptin expression – can in turn contribute to the production of acute phase reactants that influence each other in promoting chronic inflammation, underscoring leptin’s promoting effect on low- grade inflammation.

As mentioned before and as shown in Fig. 1, leptin affects both innate and adaptive immunity. In the adaptive immune response, leptin promotes T cell survival [21] by modulating the expression of anti-apoptotic proteins [22], partly explaining the reduced T cell numbers during fasting, where a significant drop in circulating lep- tin levels is observed [23].

While leptin enhances the proliferation and activation of T cells, it is noteworthy that it can exert differential effects on proliferation of naïve vs memory T cells or T effector cells (Teffs) vs. Tregs [24,25]. Specifically, leptin promotes naїve T cell survival and the production of IFN-c and IL-2, and facilitates the differentiation and activity of Th1 cells while inhibiting Th2 cells [26]. It also pro- motes IgG2a switch and inhibits IgG1 switch in B cells [6]. The activity of leptin on T cells also extends to proinflammatory Th17 cells, in which it promotes the expression of the master regulator transcription factor RAR-related orphan receptor (ROR)ct, while leptin neutralization inhibits Th17 responses [27]. At the mean- time, leptin represents a negative signal for the expansion of Tregs [24]. Leptin neutralization causes Tregs to proliferate and better suppress autoimmune responses, both in vitro and in vivo [24]. It is therefore expected that ob/ob and db/db mice display elevated numbers of Tregs [24].

Of note, freshly isolated Tregs produce leptin and express the leptin receptor, which is also expressed on additional immune cell subsets [28]. At the molecular level, leptin activates the mTOR pathway to control Tregs responsiveness [29] and Teffs functions [25]. More specifically, leptin inhibits rapamycin-induced prolifer- ation of Tregs by increasing activation of the mTOR pathway [29]. Interestingly, leptin exerts opposite effects on Teffs, where it enhances their proliferation also through modulation of the mTOR pathway [25].

2.1. Leptin signaling in immune cells

Leptin receptor expression on multiple immune cell types makes the activity of leptin influential on different immune func- tions both in mice [30] and in humans [31]. The pleiotropic biolog- ical effects of leptin can be explained by the wide distribution of leptin receptors on different types of cells, not last those ones found in non-neural tissues and that take part in the immune response. In this context, the study of the biochemical events that follow the binding of leptin to its cognate receptors have been

Monocytes/Macrophages

TRAIL CD107a

Neutrophils

Chemotaxis Infiltra�on H2O2

Eosinophils

Basophils

Chemotaxis

Chemotaxis IL-4, IL-13

Dendri�c Cell

Matura�on (MHC II, CD80, CD86, CD40)

IL-2, IL-6, TNF- CCR7

NK Cell

TLR2 IL-1 , IL-6, TNF- Phagocytosis

Innate Immunity Adap�ve Immunity

Th1

Th2

Th17

Treg

Suppression Prolifera�on

ROR t, IL-17

STAT3 MAPK

IFN-

Fig. 1. Schematic representation of the multiple effects of leptin on different types of immune cells of the innate and adaptive immune systems.

A. La Cava / Cytokine 98 (2017) 51–58 53

studied extensively and have been well characterized. Leptin receptors are class I cytokine receptors encoded by the db gene that vary in length due to alternative splicing. In mice, there are six dif- ferent isoforms that share a common extracellular and transmem- brane domain, but differ in the length of their intracellular domain. They have characteristic extracellular motifs of four cysteine resi- dues and contain the aminoacid sequence WSXWS (Trp-Ser-Xaa- Trp-Ser) and fibronectin type III domains [32]. Leptin receptors include a soluble form (Ob-Re), four short forms (Ob-Ra, Ob-Rc, Ob-Rd and Ob-Rf) and one long isoform (Ob-Rb) [33]. All have a common extracellular domain of more than 800 amino acids, a transmembrane domain of 34 amino acids, and a variable intracel- lular domain characteristic of each isoform. The main differences are in the intracellular amino acids: 302 for OB-Rb, and 34, 32 and 40, respectively, for the short forms OB-Ra, OB-Rc and OB- Rd. Signaling through Ob-Rb is considered the most important in conveying leptin effects, as this long isoform has the longest intracellular domain with 302 amino acids and is the only isoform containing functional Janus kinase (Jak)2 and signal transducers and activators of transcription (STAT) binding sites which are essential for signal transduction and transmission of leptin func- tion [28]. On the other hand, the lack of cytoplasmic (short forms) or transmembrane components (soluble receptor) results in recep- tors that contribute to the regulation of plasma leptin levels by binding leptin without transducing intracellular signals [34]. From a biochemical standpoint, Ob-R does not have an intrinsic tyrosine kinase domain but a proline-rich box 1 motif that can bind Jak2. Leptin binding to Ob-Rb causes homo-oligomerization and binding to Jak which leads to autophosphorylation of Jak2 and the phos- phorylation of intracellular Tyr985, Tyr1077, and Tyr1138 [35,36]. The phosphorylation of Tyr1138 is important for the recruitment of STAT proteins to the Ob-Rb/ Jak2 complex, leading to transcription activation of target genes including the suppressor of cytokine signaling (SOCS)3 [37–41]. In addition to SOCS3, pro- tein tyrosine phosphatase 1B (PTP1B) inhibits leptin-mediated signaling and acts by dephosphorylating Jak2 [42], whereas phos- phorylated Jak2 activates the mitogen-activated protein kinase (MAPK) cascade via recruitment of src homology 2-containing tyr- osine phosphatase (SHP2) to OB-Rb, which binds to GRB2 to signal through RAS, RAF and MEK1 for the activation of extracellular

signal-regulated kinase (ERK)1/2, p38 MAPK and p42/44 pathways [36,43–45]. An alternative pathway involves the interaction of SHP2 and GRB2 on Jak2 [46,47]. In any case, autophosphorylated Jak2 can phosphorylate insulin receptor substrate1/2 (IRS1/2) and activate phosphatidylinositol 3-kinase (PI3K)/Akt [48].

In humans, four splice variants of leptin receptor have been identified: a long OB-R isoform and three short isoforms designed huB219.1–huB219.3 [49]. Of those, the long isoform responsible for the anorexigenic effects of leptin is abundant in the hypothala- mic centers regulating food intake and can also be found on immune cells [50–52], being capable to stimulate proliferation of peripheral blood mononuclear cells [53].

3. Leptin in non-autoimmune inflammation

Alone or in combination with IL-1, leptin promotes the expres- sion of inducible nitric oxide (NO) synthase (iNOS) and COX-2 and the production of NO, prostaglandin E, IL-6, and IL-8. The effects of leptin are mediated through activation of the transcription factor nuclear factor-jB (NF-jB) and c-Jun NH2-terminal protein kinase (JNK) (with subsequent phospholipase C (PLC) and protein kinase C (PKC) activation), having NO as a key mediator of the increased synthesis of those proinflammatory mediators [54,55]. These events are responsible for leptin’s stimulation of oxidative stress, and at the cardiovascular level they result in vascular inflammation and vascular smooth muscle hypertrophy – all factors that con- tribute to atherosclerosis, hypertension, coronary heart disease and thrombosis [56]. In other system, these events produce as well proinflammatory states that are discussed below.

3.1. Leptin and atherosclerosis

Leptin can contribute to atherogenesis [57,58] by promoting the recruitment of monocytes to the intima, eliciting foam cell formation, and favoring secretion of proinflammatory and athero- genic cytokines [59,60], in addition to altering cardiomyocyte structure and function [61]. This is because leptin receptors are present within lesions of atherosclerosis patients [56], and leptin-deficient ob/ob mice are resistant to atherosclerosis [62]. Also, low-density lipoprotein (LDL) receptor-deficient ob/ob

54 A. La Cava / Cytokine 98 (2017) 51–58

(LDL-R�/�/ob/ob) mice show a considerable reduction in atheroscle- rotic lesions as compared to LDL-R�/� mice with intact leptin signaling [63].

Leptin levels are also positively correlated with levels of fibrino- gen, plasminogen activator inhibitor-1, von Willebrand factor, and factor VIIa, and negatively correlated with protein C and tissue plasminogen activator, thus affecting fibrinolysis and favoring arterial thrombosis [64–68].

3.2. Leptin and type 2 diabetes

Since leptin modulates glucose homeostasis and inhibits insulin synthesis and secretion, the development of type 2 diabetes in ob/ob and db/db mice is dramatically attenuated by leptin adminis- tration [69,70]. In addition to decreasing insulin secretion via a direct action on the pancreatic b cells, leptin also enhances glucose uptake and oxidation in skeletal muscle and suppresses the hepatic production of glucose [71–73]. At the molecular level, leptin sig- nals in pancreatic b cells through Jak-STAT and interferes with cAMP and the activation of PI3 kinase [74]. A role of leptin in diabetic nephropathy is as well suggested by the observation that leptin deficient ob/ob mice are relatively resistant to the develop- ment of diabetic glomerulopathy, and by the finding leptin levels are increased in albuminuric type 2 diabetes patients (where uri- nary leptin positively correlates with urinary albumin-creatinine ratio and inversely correlate with glomerular filtration rate) [75].

In the metabolic syndrome - a combination of abdominal obe- sity, high blood pressure, high blood glucose, low HDL, elevated cholesterol and high triglycerides that increase the risk of heart disease and diabetes, high leptin levels predict disease worsening independently of obesity [76]. Those patients may also be affected by non-alcoholic steatohepatitis (a liver disease characterized by fat accumulation in hepatocytes), where leptin could contribute to fat accumulation through a reduced hepatic oxidation and an increased synthesis of free fatty acids that would cause liver inflammation and fibrosis through local lipid accumulation and peroxidation [77–79].

3.3. Renal inflammation

Leptin is mainly cleared by the kidney [80], which is an organ targeted by leptin activities [81]. Indeed, leptin-deficient ob/ob mice are protected from renal inflammation and nephrotoxic nephritis [82].

The direct and indirect effects of leptin on the kidney include natriuresis, increased sympathetic nervous activity, and the stimu- lation of reactive oxygen species [83]. Moreover, leptin is involved in the development of glomerulosclerosis through a paracrine TGF- b pathway (between glomerular endothelial and mesangial cells) that promotes deposition of extracellular matrix and proteinuria [84].

3.4. Chronic obstructive pulmonary disease (COPD)

Among the inflammatory conditions characterized by a strong tendency to chronicity, leptin has been considered an inflamma- tory marker of airway inflammation and a possible contributor to severity of COPD, a chronic inflammatory disease of the lung [85].

3.5. Behçet’s disease

Also in Behçet’s disease (a chronic, systemic inflammatory dis- order with generalized vasculitis), the levels of serum leptin are increased, particularly in patients with long disease duration, where they correlate with disease activity [86].

3.6. Pelvic endometriosis

Leptin elevation in the peritoneal fluid of patients with endometriosis positively correlates with the clinical stage of the disease [87,88], although no differences are found in serum leptin concentration of endometriosis patients and controls [89]. Leptin’s contribution to pelvic endometriosis could be related to the ability of leptin to promote neoangiogenesis and the production of proin- flammatory cytokines [90].

3.7. Leptin and cancer

Given the immunomodulatory properties of leptin, considera- tions have been made on the possibility that leptin could influence tumorigenesis, particularly in hepatocellular carcinoma and pros- tate cancer [91]. The idea is that leptin might facilitate cancer cell progression by promoting inflammation, together with cell prolif- eration and migration while inhibiting apoptosis. Additionally, tumors and metastasis depend on angiogenesis, and leptin influ- ences angiogenesis significantly [6]. However, insufficient informa- tion is currently available to draw conclusions, and further research and longitudinal studies are required to delineate both specific and additive effects of leptin in cancer [92].

3.8. Leptin and infection

In the course of acute inflammation, infection and sepsis, leptin levels increase favored by the presence of bacterial lipopolysaccha- ride and the increase in cytokines such as TNF-a, IL-6, and IL-1b [93]. In humans, plasma leptin is elevated in septic patients and positively correlates with patients’ survival [94,95]. However, in some acute inflammatory conditions such as acute experimental endotoxemia and newborn sepsis, no increased levels of serum leptin are found [96,97].

In tuberculosis and pediatric HIV patients, leptinemia is reduced [98,99]. In HIV infection, highly active anti-retroviral ther- apy (HAART) associates with increased leptinemia, together with the amelioration of the clinical picture and improvement of CD4+

T cell counts [100]. In bacterial infection, leptin proinflammatory activities

(through TNF-a and IL-6 induction) seem to contribute to patho- gens clearance. Leptin-deficient ob/ob mice develop severe disease and die of Klebsiella infection more rapidly than wild-type mice, and their elevated susceptibility to LPS-induced lethality can be reversed by leptin administration [101–105].

4. Leptin and autoimmunity

Elevated levels of circulating leptin have been associated with multiple autoimmune diseases, both in humans and in animal models of human autoimmunity [106], as discussed below.

4.1. Leptin and type-1 diabetes (T1D)

Leptin accelerates T1D onset and progression in nonobese dia- betic (NOD) mice by stimulating autoimmune destruction of b- cells and by increasing IFN-c production [107]. Also, a spontaneous mutation of ObR (LepRdb5J) in T1D-prone NOD mice inhibits T1D development [108]. Moreover, in ob/ob diabetic rats, systemic administration of leptin reversed ketoacidosis and normalizes blood glucose concentration by decreasing the delivery of glycerol and fatty acids to the liver, also reducing availability of acetyl-CoA (an inhibitor of the conversion of pyruvate to glucose) [109]. Although these data suggest a promoting role of leptin in T1D, also suggested by the finding of elevated circulating levels of leptin in

A. La Cava / Cytokine 98 (2017) 51–58 55

T1D patients [110], recent data indicated that leptin treatment could reverse hyperglycemia in animal models of poorly controlled T1D (possibly through the suppression of glucagon production and/or responsiveness to this hormone) [109].

4.2. Leptin and multiple sclerosis

Leptin deficient ob/ob mice and leptin receptor-deficient db/db mice are resistant to the development of several experimentally- induced autoimmune diseases [6], among which experimental autoimmune encephalomyelitis (EAE) [111] – an animal model of human multiple sclerosis (MS). Resistance to EAE is reversed by leptin replacement while administration of leptin worsens EAE, indicating a key role of this adipokine in the disease susceptibility [111]. Furthermore, leptin neutralization improved clinical score and delayed EAE progression [112]. In MS patients, leptin produc- tion is increased in both serum and cerebrospinal fluid, and inver- sely correlates with the numbers of circulating Tregs [113].

4.3. Leptin and inflammatory bowel disease (IBD)

Although experimental colitis in rats resulted in increased lep- tin levels in association with weight loss [114], and ob/ob mice dis- played resistance to acute and chronic intestinal inflammation [115], conflicting data and insufficient clinical studies may not allow at present to draw unequivocal conclusions on a possible role of leptin in IBD.

4.4. Leptin and autoimmune arthritis

ob/ob and db/db mice develop a milder form of antigen-induced arthritis than wild-type controls, and have markedly reduced antigen-specific autoreactive T cell proliferation and proinflamma- tory cytokine production [116]. In chondrocytes, leptin induces NOS activation, in synergy with IFN-c and IL-1 [117], in addition to metalloproteases activation, apoptosis, and chondrocyte pheno- type loss [118].

However, the role of leptin in the pathogenesis of rheumatoid arthritis (RA) is controversial. High levels of leptin both systemi- cally and in the joints have been reported by some authors - also correlating with disease activity [119] - but other studies found no changes or even low levels of leptin and no correlations with disease biomarkers or activity scores [120].

4.5. Leptin and systemic lupus erythematosus

Leptin increase in SLE does not correlate with disease activity but it can contribute to elevated cardiovascular risk [121] by inducing proinflammatory high-density lipoproteins and atherosclerosis [122]. The propathogenic effects of leptin in SLE can be ascribed, at last in part, to its promoting activities on proinflammatory Th17 cells [27] and the facilitated autoantibody production that is con- comitant to the inhibition of immunoregulatory responses [123]. Other mechanisms include leptin’s promotion of the activity and survival of autoreactive T cell via an increased expression of the anti-apoptotic molecule Bcl-2 [124,22]. Notably, leptin neutraliza- tion in lupus-prone mice inhibits proinflammatory responses and SLE manifestations [27,123]. Similarly, a reduction in circulating leptin levels induced by fasting protects lupus mice from SLE via mechanisms that include an expansion of peripheral Tregs [125].

4.6. Leptin in psoriasis

Although an increase in leptin in psoriasis patients seems to parallel the severity of the disease, the data on a promoting role of leptin in the disease remain controversial [126,127].

5. Conclusions

Given the contribution of the proinflammatory activity of leptin to autoimmune and non-autoimmune inflammation, it has been suggested to limit leptin bioavailability in those conditions through antibody-based antagonism [3]. In non-autoimmune inflammatory conditions such cardiovascular and metabolic dis- eases, leptin inhibition could negatively influence the development and progression of the disease, whereas in autoimmunity it could reduce immune hyperactivity and slow the progression of chronic inflammation leading to target tissue damage.

It has nonetheless to be taken into account that lowered leptin levels could negatively affect effector immune responses during infection, and thus targeted approaches considering selective tar- geting of the leptin pathway might be considered to reduce this possibility. For example, useful leptin-based targets could be SOCS3 (an important factor of leptin resistance and negative feed- back), PTP1B (which dephosphorylates Jak2 on OB-R), and SHP2 (which is critical for leptin signaling through downregulation of the ObRb-STAT3 pathway and the promotion of ERK signaling) [128,129].

Funding

This work was supported in part by the National Institutes of Health grant AI109677.

References

[1] A. La Cava, C. Alviggi, G. Matarese, Unraveling the multiple roles of leptin in inflammation and autoimmunity, J. Mol. Med. 82 (2004) 4–11.

[2] A. La Cava, Proinflammatory activities of leptin in non-autoimmune conditions, Inflamm. Allergy Drug Targets 11 (2012) 298–302.

[3] G. Matarese, A. La Cava, V. Sanna, G.M. Lord, R.I. Lechler, S. Fontana, S. Zappacosta, Balancing susceptibility to infection and autoimmunity: a role for leptin?, Trends Immunol 23 (2002) 182–187.

[4] G. Matarese, C. Procaccini, V. De Rosa, T.L. Horvath, A. La Cava, Regulatory T cells in obesity: the leptin connection, Trends Mol. Med. 16 (2010) 247–256.

[5] F. Zhang, M.B. Basinski, J.M. Beals, S.L. Briggs, L.M. Churgay, D.K. Clawson, R.D. DiMarchi, T.C. Furman, J.E. Hale, H.M. Hsiung, B.E. Schoner, D.P. Smith, X.Y. Zhang, J.P. Wery, R.W. Schevitz, Crystal structure of the obese protein leptin- E100, Nature 387 (1997) 206–209.

[6] A. La Cava, G. Matarese, The weight of leptin in immunity, Nat. Rev. Immunol. 4 (2004) 371–379.

[7] I.S. Farooqi, G. Matarese, G.M. Lord, J.M. Keogh, E. Lawrence, C. Agwu, V. Sanna, S.A. Jebb, F. Perna, S. Fontana, R.I. Lechler, A.M. DePaoli, S. O’Rahilly, Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency, J. Clin. Invest. 110 (2002) 1093–1103.

[8] J.K. Howard, G.M. Lord, G. Matarese, S. Vendetti, M.A. Ghatei, M.A. Ritter, R.I. Lechler, S.R. Bloom, Leptin protects mice from starvation-induced lymphoid atrophy and increases thymic cellularity in ob/ob mice, J. Clin. Invest. 104 (1999) 1051–1059.

[9] M. Ozata, I.C. Ozdemir, J. Licinio, Human leptin deficiency caused by a missense mutation: multiple endocrine defects, decreased sympathetic tone, and immune system dysfunction indicate new targets for leptin action, greater central than peripheral resistance to the effects of leptin, and spontaneous correction of leptin-mediated defects, J. Clin. Endocrinol. Metab. 84 (1999) 3686–3895.

[10] C. Gabay, M. Dreyer, N. Pellegrinelli, R. Chicheportiche, C.A. Meier, Leptin directly induces the secretion of interleukin 1 receptor antagonist in human monocytes, J. Clin. Endocrinol. Metab 86 (2001) 783–791.

[11] J. Santos-Alvarez, R. Goberna, V. Sanchez-Margalet, Human leptin stimulates proliferation and activation of human circulating monocytes, Cell. Immunol. 194 (1999) 6–11.

[12] H. Zarkesh-Esfahani, G. Pockley, R.A. Metcalfe, M. Bidlingmaier, Z. Wu, A. Ajami, A.P. Weetman, C.J. Strasburger, R.J. Ross, High-dose leptin activates human leukocytes via receptor expression on monocytes, J. Immunol. 167 (2001) 4593–4599.

[13] P. Mancuso, C. Canetti, A. Gottschalk, P.K. Tithof, M. Peters-Golden, Leptin augments alveolar macrophage leukotriene synthesis by increasing phospholipase activity and enhancing group IVC iPLA2 (cPLA2c) protein expression, Am. J. Physiol. Lung Cell. Mol. Physiol. 287 (2004) L497–L502.

[14] G. Fantuzzi, Adipose tissue, adipokines, and inflammation, J. Allergy Clin. Immunol. 115 (2005) 911–919.

[15] A. Bruno, S. Conus, I. Schmid, H.U. Simon, Apoptotic pathways are inhibited by leptin receptor activation in neutrophils, J. Immunol. 174 (2005) 8090–8096.

56 A. La Cava / Cytokine 98 (2017) 51–58

[16] C.K. Wong, P.F. Cheung, C.W. Lam, Leptin-mediated cytokine release and migration of eosinophils: implications for immunopathophysiology of allergic inflammation, Eur. J. Immunol. 37 (2007) 2337–2348.

[17] Y. Zhao, R. Sun, L. You, C. Gao, Z. Tian, Expression of leptin receptors and response to leptin stimulation of human natural killer cell lines, Biochem. Biophys. Res. Commun. 300 (2003) 247–252.

[18] Q.L. Lam, S. Liu, X. Cao, L. Lu, Involvement of leptin signaling in the survival and maturation of bone marrow-derived dendritic cells, Eur. J. Immunol. 36 (2006) 3118–3130.

[19] R.E. Landman, J.J. Puder, E. Xiao, P.U. Freda, M. Ferin, S.L. Warldaw, Endotoxin stimulates leptin in the human and nonhuman primate, J. Clin. Endocrinol. Metab. 88 (2003) 1285–1291.

[20] R. Faggioni, G. Fantuzzi, J. Fuller, C.A. Dinarello, K.R. Feingold, C. Grunfeld, IL- 1b mediates leptin induction during inflammation, Am. J. Physiol. 274 (1998) R204–R208.

[21] P. Fernández-Riejos, R. Goberna, V. Sánchez-Margalet, Leptin promotes cell survival and activates Jurkat T lymphocytes by stimulation of mitogen- activated protein kinase, Clin. Exp. Immunol. 151 (2008) 505–518.

[22] G. Amarilyo, N. Iikuni, F.-D. Shi, A. Liu, G. Matarese, A. La Cava, Leptin promotes lupus T-cell autoimmunity, Clin. Immunol. 149 (2013) 530–533.

[23] R. Faggioni, K.R. Feingold, C. Grunfeld, Leptin regulation of the immune response and the immunodeficiency of malnutrition, FASEB J. 15 (2001) 2565–2571.

[24] V. De Rosa, C. Procaccini, G. Calì, G. Pirozzi, S. Fontana, S. Zappacosta, A. La Cava, G. Matarese, A key role of leptin in the control of regulatory T cell proliferation, Immunity 26 (2007) 241–255.

[25] C. Procaccini, V. De Rosa, M. Galgani, F. Carbone, S. Cassano, D. Greco, K. Qian, P. Auvinen, G. Calì, G. Stallone, L. Formisano, A. La Cava, G. Matarese, Leptin- induced mTOR activation defines a specific molecular and transcriptional signature controlling CD4+ effector T cell responses, J. Immunol. 189 (2012) 2941–2953.

[26] G.M. Lord, G. Matarese, J.K. Howard, R.J. Baker, S.R. Bloom, R.I. Lechler, Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression, Nature 394 (1998) 897–901.

[27] Y. Yu, Y. Liu, F.-D. Shi, H. Zou, G. Matarese, A. La Cava, Cutting edge: leptin- induced RORct expression in CD4+ T cells promotes Th17 responses in systemic lupus erythematosus, J. Immunol. 190 (2013) 3054–3058.

[28] C. Procaccini, E.V. Lourenço, G. Matarese, A. La Cava, Leptin signaling: a key pathway in immune responses, Curr. Signal Transduct. Ther. 4 (2009) 22–30.

[29] C. Procaccini, V. De Rosa, M. Galgani, L. Abanni, G. Calì, A. Porcellini, F. Carbone, S. Fontana, T.L. Horvath, A. La Cava, G. Matarese, An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness, Immunity 33 (2010) 929–941.

[30] S. Loffreda, S.Q. Yang, H.Z. Lin, C.L. Karp, M.L. Brengman, D.J. Wang, A.S. Klein, G.B. Bulkley, C. Bao, P.W. Noble, M.D. Lane, A.M. Diehl, Leptin regulates proinflammatory immune responses, FASEB J. 12 (1998) 57–65.

[31] C. Martín-Romero, J. Santos-Alvarez, R. Goberna, V. Sánchez-Margalet, Human leptin enhances activation and proliferation of human circulating T lymphocytes, Cell. Immunol. 199 (2000) 15–24.

[32] J.F. Bazan, Structural design and molecular evolution of a cytokine receptor superfamily, Proc. Natl. Acad. Sci. USA 87 (1990) 6934–6938.

[33] H. Fei, J.J. Okano, C. Li, G.H. Lee, C. Zhao, R. Darnell, J.M. Friedman, Anatomic localization of alternatively spliced leptin receptors (Ob-R) in mouse brain and other tissues, Proc. Natl. Acad. Sci. USA 94 (1997) 7001–7005.

[34] J.L. Chan, S. Bluher, N. Yiannakouris, M.A. Suchard, J. Kratzsch, C.S. Mantzoros, Regulation of circulating soluble leptin receptor levels by gender, adiposity, sex steroids, and leptin: observational and interventional studies in humans, Diabetes 51 (2002) 2105–2112.

[35] C. Kloek, A.K. Haq, S.L. Dunn, H.J. Lavery, A.S. Banks, M.G. Myers Jr., Regulation of Jak kinases by intracellular leptin receptor sequences, J. Biol. Chem. 277 (2002) 41547–41555.

[36] A.S. Banks, S.M. Davis, S.H. Bates, M.G. Myers Jr., Activation of downstream signals by the long form of the leptin receptor, J. Biol. Chem. 275 (2000) 14563–14572.

[37] P. Hekerman, J. Zeidler, S. Bamberg-Lemper, H. Knobelspies, D. Lavens, J. Tavernier, H.G. Joost, W. Becker, Pleiotropy of leptin receptor signalling is defined by distinct roles of the intracellular tyrosines, FEBS J. 272 (2005) 109– 119.

[38] H. Cui, F. Cai, D.D. Belsham, Leptin signaling in neurotensin neurons involves STAT, MAP kinases ERK1/2, and p38 through c-Fos and ATF1, FASEB J. 20 (2006) 2654–2656.

[39] E. Mansour, F.G. Pereira, E.P. Araújo, M.E. Amaral, J. Morari, N.R. Ferraroni, D.S. Ferreira, I. Lorand-Metze, L.A. Velloso, Leptin inhibits apoptosis in thymus through a janus kinase-2-independent, insulin receptor substrate-1/ phosphatidylinositol-3 kinase-dependent pathway, Endocrinology 147 (2006) 5470–5479.

[40] C. Bjorbaek, J.K. Elmquist, J.D. Frantz, S.E. Shoelson, J.S. Flier, Identification of SOCS-3 as a potential mediator of central leptin resistance, Mol. Cell. 1 (1998) 619–625.

[41] C. Bjorbaek, K. El-Haschimi, J.D. Frantz, J.S. Flier, The role of SOCS-3 in leptin signaling and leptin resistance, J. Biol. Chem. 274 (1999) 30059–30065.

[42] J.M. Zabolotny, K.K. Bence-Hanulec, A. Stricker-Krongrad, F. Haj, Y. Wang, Y. Minokoshi, Y.B. Kim, J.K. Elmquist, L.A. Tartaglia, B.B. Kahn, B.G. Neel, PTP1B regulates leptin signal transduction in vivo, Dev. Cell 2 (2002) 385–387.

[43] M.G. Myers Jr., Leptin receptor signaling and the regulation of mammalian physiology, Rec. Prog. Horm. Res. 59 (2004) 287–304.

[44] G.R. van den Brink, T. O’Toole, J.C. Hardwick, D.E. van den Boogaardt, H.H. Versteeg, S.J. van Deventer, M.P. Peppelenbosch, Leptin signaling in human peripheral blood mononuclear cells, activation of p38 and p42/44 mitogen- activated protein (MAP) kinase and p70 S6 kinase, Mol. Cell. Biol. Res. Commun. 4 (2000) 144–150.

[45] C. Bjorbaek, R.M. Buchholz, S.M. Davis, S.H. Bates, D.D. Pierroz, H. Gu, B.G. Neel, M.G. Myers Jr, J.S. Flier, Divergent roles of SHP-2 in ERK activation by leptin receptors, J. Biol. Chem. 276 (2001) 4747–4755.

[46] C. Bjorbaek, S. Uotani, B. da Silva, J.S. Flier, Divergent signaling capacities of the long and short isoforms of the leptin receptor, J. Biol. Chem. 272 (1997) 32686–32695.

[47] M.R. Stofega, J. Herrington, N. Billestrup, C. Carter-Su, Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B, Mol. Endocrinol. 14 (2000) 1338–1350.

[48] Q.L. Lam, L. Lu, Role of leptin in immunity, Cell. Mol. Immunol. 4 (2007) 1–13. [49] J. Dam, R. Jockers, Hunting for the functions of short leptin receptor isoforms,

Mol. Metab. 2 (2013) 327–328. [50] B. Mattioli, E. Straface, M.G. Quaranta, L. Giordani, M. Viora, Leptin promotes

differentiation and survival of human dendritic cells and licenses them for Th1 priming, J. Immunol. 174 (2005) 6820–6828.

[51] Z. Tian, R. Sun, H. Wei, B. Gao, Impaired natural killer (NK) cell activity in leptin receptor deficient mice: leptin as a critical regulator in NK cell development and activation, Biochem. Biophys. Res. Commun. 298 (2002) 297–302.

[52] V. Sanchez-Margalet, C. Martin-Romero, C. Gonzalez-Yanes, R. Goberna, J. Rodriguez-Bano, M.A. Muniain, Leptin receptor (Ob-R) expression is induced in peripheral blood mononuclear cells by in vitro activation and in vivo in HIV-infected patients, Clin. Exp. Immunol. 129 (2002) 119–124.

[53] V. Sanchez-Margalet, C. Martín-Romero, J. Santos-Alvarez, R. Goberna, S. Najib, C. Gonzalez-Yanes, Role of leptin as an immunomodulatory of blood mononuclear cells: mechanisms of action, Clin. Exp. Immunol. 133 (2003) 11–19.

[54] K. Takekoshi, K. Ishii, T. Nanmoku, S. Shibuya, Y. Kawakami, K. Isobe, T. Nakai, Leptin stimulates catecholamine synthesis in a PKC-dependent manner in cultured porcine adrenal medullary chromaffin cells, Endocrinology 142 (2001) 4861–4871.

[55] K. Vuolteenaho, A. Koskinen, M. Kukkonen, R. Nieminen, U. Päivärinta, T. Moilanen, E. Moilanen, Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage-mediator role of NO in leptin- induced PGE 2, IL-6, and IL-8 production, Mediators Inflamm. 2009 (2009) 345838.

[56] G. Matarese, C. Mantzoros, A. La Cava, Leptin and adipocytokines: bridging the gap between immunity and atherosclerosis, Curr. Pharm. Des. 13 (2007) 3676–3680.

[57] A.M. Brennan, J.H. Lee, S. Tsiodras, J.L. Chan, J. Doweiko, S.N. Chimienti, S.G. Wadhwa, A.W. Karchmer, C.S. Mantzoros, R-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans, Eur. J. Endocrinol. 160 (2009) 173–176.

[58] J. Beltowski, Leptin and atherosclerosis, Atherosclerosis 189 (2006) 47–60. [59] S.I. Yamagishi, D. Edelstein, X.L. Du, Y. Kaneda, M. Guzmán, M. Brownlee,

Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A, J. Biol. Chem. 276 (2001) 25096–25100.

[60] L. O’Rourke, L.M. Gronning, S.J. Yeaman, P.R. Shepherd, Glucose-dependent regulation of cholesterol ester metabolism in macrophages by insulin and leptin, J. Biol. Chem. 277 (2002) 42557–42562.

[61] R. Yang, L.A. Barouch, Leptin signaling and obesity: cardiovascular consequences, Circ. Res. 101 (2007) 545–559.

[62] H. Gonzalez-Navarro, D.J. Burks, V. Andres, Murine models to investigate the influence of diabetic metabolism on the development of atherosclerosis and restenosis, Front. Biosci. 12 (2007) 4439–4455.

[63] S. Taleb, O. Herbin, H. Ait-Oufella, W. Verreth, P. Gourdy, V. Barateau, R. Merval, B. Esposito, K. Clément, P. Holvoet, A. Tedgui, Z. Mallat, Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis, Arterioscler. Thromb. Vasc. Biol. 27 (2007) 2691–2698.

[64] P.F. Bodary, R.J. Westrick, K.J. Wickenheiser, Y. Shen, D.T. Eitzman, Effect of leptin on arterial thrombosis following vascular injury in mice, JAMA 287 (2002) 1706–1709.

[65] S. Konstantinides, K. Schäfer, S. Koschnick, D.J. Loskutoff, Leptin-dependent platelet aggregation and arterial thrombosis suggests a mechanism for atherothrombotic disease in obesity, J. Clin. Invest. 108 (2001) 1533–1540.

[66] V. De Mitrio, G. De Pergola, R. Vettor, R. Marino, M. Sciaraffia, C. Pagano, F.A. Scaraggi, L. Di Lorenzo, R. Giorgino, Plasma plasminogen activator inhibitor-I is associated with plasma leptin irrespective of body mass index, body fat mass, and plasma insulin and metabolic parameters in premenopausal women, Metabolism 48 (1999) 960–964.

[67] S. Soderberg, T. Olsson, M. Eliasson, O. Johnson, B. Ahrén, Plasma leptin levels are associated with abnormal fibrinolysis in men and postmenopausal women, J. Int. Med. 245 (1999) 533–543.

[68] N.F. Chu, D. Spiegelman, G.S. Hotamisligil, N. Rifai, M. Stampfer, E.B. Rimm, Plasma insulin, leptin, and soluble TNF receptors levels in relation to obesity-

A. La Cava / Cytokine 98 (2017) 51–58 57

related atherogenic and thrombogenic cardiovascular disease risk factors among men, Atherosclerosis 157 (2001) 495–503.

[69] M.A. Pelleymounter, M.J. Cullen, M.B. Baker, R. Hecht, D. Winters, T. Boone, F. Collins, Effects of the obese gene product on body weight regulation in ob/ob mice, Science 269 (1995) 540–543.

[70] T.J. Kowalski, S.M. Liu, R.L. Leibel, S.C. Chua Jr, Transgenic complementation of leptin-receptor deficiency. I. Rescue of the obesity/diabetes phenotype of LEPR-null mice expressing a LEPR-B transgene, Diabetes 50 (2001) 425–435.

[71] S. Kamohara, R. Burcelin, J.L. Halaas, J.M. Friedman, M.J. Charron, Acute stimulation of glucose metabolism in mice by leptin treatment, Nature 389 (1997) 374–377.

[72] J.L. Wang, N. Chinookoswong, S. Scully, M. Qi, Z.Q. Shi, Differential effects of leptin in regulation of tissue glucose utilization in vivo, Endocrinology 140 (1999) 2117–2124.

[73] L. Rossetti, D. Massillon, N. Barzilai, P. Vuguin, W. Chen, M. Hawkins, J. Wu, J. Wang, Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action, J. Biol. Chem. 272 (1997) 27758–27763.

[74] A.Z. Zhao, K.E. Bornfeldt, J.A. Beavo, Leptin inhibits insulin secretion by activation of phosphodiesterase 3B, J. Clin. Invest. 102 (1998) 869–873.

[75] B. Fruehwald-Schultes, W. Kern, J. Beyer, T. Forst, A. Pfützner, A. Peters, Elevated serum leptin concentrations in type 2 diabetic patients with microalbuminuria and macroalbuminuria, Metabolism 48 (1999) 1290–1293.

[76] P.W. Franks, S. Brage, J. Luan, U. Ekelund, M. Rahman, I.S. Farooqi, I. Halsall, S. O’Rahilly, N.J. Wareham, Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity, Obes. Res. 13 (2005) 1476–1484.

[77] S.G. Sheth, F.D. Gordon, S. Chopra, Nonalcoholic steatohepatitis, Ann. Int. Med. 126 (1997) 137–145.

[78] S. Chitturi, G. Farrell, L. Frost, A. Kriketos, R. Lin, C. Fung, C. Liddle, D. Samarasinghe, J. George, Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?, Hepatology 36 (2002) 403–409

[79] Y. Kamada, T. Takehara, N. Hayashi, Adipocytokines and liver disease, J. Gastroenterol. 43 (2008) 811–822.

[80] F. Cumin, H.P. Baum, N. Levens, Leptin is cleared from the circulation primarily by the kidney, Int. J. Obes. Relat. Metab. Disord. 20 (1996) 1120– 1126.

[81] C. Serradeil-Le Gal, D. Raufaste, G. Brossard, B. Pouzet, E. Marty, J.P. Maffrand, G. Le Fur, Characterization and localization of leptin receptors in the rat kidney, FEBS Lett. 404 (1997) 185–191.

[82] R.M. Tarzi, H.T. Cook, I. Jackson, C.D. Pusey, G.M. Lord, Leptin-deficient mice are protected from accelerated nephrotoxic nephritis, Am. J. Pathol. 164 (2004) 385–390.

[83] G. Wolf, F.N. Ziyadeh, Leptin and renal fibrosis, Contrib. Nephrol. 151 (2006) 175–183.

[84] G. Wolf, A. Hamann, D.C. Han, U. Helmchen, F. Thaiss, F.N. Ziyadeh, R.A. Stahl, Leptin stimulates proliferation and TGF-b expression in renal glomerular endothelial cells: potential role in glomerulosclerosis, Kidney Int. 56 (1999) 860–872.

[85] R. Broekhuizen, J.H. Vernooy, A.M. Schols, M.A. Dentener, E.F. Wouters, Leptin as local inflammatory marker in COPD, Respir. Med. 99 (2005) 70–74.

[86] C. Evereklioglu, H.S. Inalöz, N. Kirtak, S. Doganay, M. Bülbül, E. Ozerol, H. Er, E. Ozbek, Serum leptin concentration is increased in patients with Behçet’s syndrome and is correlated with disease activity, Br. J. Dermatol. 147 (2002) 331–336.

[87] G. Matarese, C. Alviggi, V. Sanna, J.K. Howard, G.M. Lord, C. Carravetta, S. Fontana, R.I. Lechler, S.R. Bloom, G. De Placido, Increased leptin levels in serum and peritoneal fluid of patients with pelvic endometriosis, J. Clin. Endocrinol. Metab. 85 (2000) 2483–2487.

[88] N.G. Mahutte, I.M. Matalliotakis, A.G. Goumenou, S. Vassiliadis, G.E. Koumantakis, A. Arici, Inverse correlation between peritoneal fluid leptin concentrations and the extent of endometriosis, Hum. Reprod. 18 (2003) 1205–1209.

[89] I. Wertel, M. Gogacz, G. Polak, J. Jakowicki, J. Kotarski, Leptin is not involved in the pathophysiology of endometriosis-related infertility, Eur. J. Obstet. Gynecol. Reprod. Biol. 119 (2005) 206–209.

[90] L.C. Giudice, L.C. Kao, Endometriosis, Lancet 364 (2004) 1789–1799. [91] C. Cai, F.D. Shi, G. Matarese, A. La Cava, Leptin as clinical target, Rec. Pat.

Inflamm. Allergy Drug Discov. 3 (2009) 160–166. [92] M. Galgani, A. Di Giacomo, G. Matarese, A. La Cava, The Yin and Yang of CD4+

regulatory T cells in autoimmunity and cancer, Curr. Med. Chem. 16 (2009) 4626–4631.

[93] P. Sarraf, R.C. Frederich, E.M. Turner, G. Ma, N.T. Jaskowiak, D.J. Rivet 3rd, J.S. Flier, B.B. Lowell, D.L. Fraker, H.R. Alexander, Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia, J. Exp. Med. 185 (1997) 171–175.

[94] F. Arnalich, J. Lopez, R. Codoceo, M. Jimenez, R. Madero, C. Montiel, Relationship of plasma leptin to plasma cytokines and human survival in sepsis and septic shock, J. Infect. Dis. 180 (1999) 908–911.

[95] S.R. Bornstein, J. Licinio, R. Tauchnitz, L. Engelmann, A.B. Negrão, P. Gold, G.P. Chrousos, Plasma leptin levels are increased in survivors of acute sepsis: associated loss of diurnal rhythm, in cortisol and leptin secretion, J. Clin. Endocrinol. Metab. 83 (1998) 280–283.

[96] S.R. Bornstein, H.L. Preas, G.P. Chrousos, A.F. Suffredini, Circulating leptin levels during acute experimental endotoxemia and antiinflammatory therapy in humans, J. Infect Dis. 178 (1998) 887–890.

[97] E. Koç, G. Ustündağ, D. Aliefendioğlu, E. Ergenekon, A. Bideci, Y. Atalay, Serum leptin levels and their relationship to tumor necrosis factor-a and interleukin-6 in neonatal sepsis, J. Pediatr. Endocrinol. Metab. 16 (2003) 1283–1287.

[98] K.E. Yarasheski, J.J. Zachwieja, M.M. Horgan, W.G. Powderly, J.V. Santiago, M. Landt, Serum leptin concentrations in human immunodeficiency virus- infected men with low adiposity, Metabolism 46 (1997) 303–305.

[99] R. van Crevel, E. Karyadi, M.G. Netea, H. Verhoef, R.H. Nelwan, C.E. West, J.W. van der Meer, Decreased plasma leptin concentrations in tuberculosis patients are associated with wasting and inflammation, J. Clin. Endocrinol. Metab. 87 (2002) 758–763.

[100] J.J. Pinzone, M.L. Fox, M.K. Sastry, D.M. Parenti, G.L. Simon, Plasma leptin concentration increases early during highly active antiretroviral therapy for acquired immunodeficiency syndrome, independent of body weight, J. Endocrinol. Invest. 28 (2005) RC1–RC3.

[101] A. Hsu, D.M. Aronoff, J. Phipps, D. Goel, P. Mancuso, Leptin improves pulmonary bacterial clearance and survival in ob/ob mice during pneumococcal pneumonia, Clin. Exp. Immunol. 150 (2007) 332–339.

[102] C.W. Wieland, M.E. Stegenga, S. Florquin, G. Fantuzzi, T. van der Poll, Leptin and host defense against Gram-positive and Gram-negative pneumonia in mice, Shock 25 (2006) 414–419.

[103] R. Faggioni, G. Fantuzzi, C. Gabay, A. Moser, C.A. Dinarello, K.R. Feingold, C. Grunfeld, Leptin deficiency enhances sensitivity to endotoxin-induced lethality, Am. J. Physiol. 276 (1999) R136–R142.

[104] R. Faggioni, A. Moser, K.R. Feingold, C. Grunfeld, Reduced leptin levels in starvation increase susceptibility to endotoxic shock, Am. J. Pathol. 156 (2000) 1781–1787.

[105] E. Xiao, L. Xia-Zhang, N.R. Vulliemoz, M. Ferin, S.L. Wardlaw, Leptin modulates inflammatory cytokine and neuroendocrine responses to endotoxin in the primate, Endocrinology 144 (2003) 4350–4353.

[106] J. Hutcheson, Adipokines influence the inflammatory balance in autoimmunity, Cytokine 75 (2015) 272–279.

[107] G. Matarese, V. Sanna, R.I. Lechler, N. Sarvetnick, S. Fontana, S. Zappacosta, A. La Cava, Leptin accelerates autoimmune diabetes in female NOD mice, Diabetes 51 (2002) 1356–1361.

[108] C.H. Lee, Y.G. Chen, J. Chen, P.C. Reifsnyder, D.V. Serreze, M. Clare-Salzler, M. Rodriguez, C. Wasserfall, M.A. Atkinson, E.H. Leiter, Novel leptin receptor mutation in NOD/LtJ mice suppresses type 1 diabetes progression: II. Immunologic analysis, Diabetes 55 (2006) 171–178.

[109] R.J. Perry, X.M. Zhang, D. Zhang, N. Kumashiro, J.P. Camporez, G.W. Cline, D.L. Rothman, G.I. Shulman, Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis, Nat. Med. 20 (2014) 759–763.

[110] G. Iacobellis, S. Diaz, A. Mendez, R. Goldberg, Increased epicardial fat and plasma leptin in type 1 diabetes independently of obesity, Nutr. Metab. Cardiovasc. Dis. 24 (2014) 72572–72579.

[111] V. Sanna, A. Di Giacomo, A. La Cava, R.I. Lechler, S. Fontana, S. Zappacosta, G. Matarese, Leptin surge precedes onset of autoimmune encephalomyelitis and correlates with development of pathogenic T cell responses, J. Clin. Invest. 111 (2003) 241–250.

[112] V. De Rosa, C. Procaccini, A. La Cava, P. Chieffi, G.F. Nicoletti, S. Fontana, S. Zappacosta, G. Matarese, Leptin neutralization interferes with pathogenic T cell autoreactivity in autoimmune encephalomyelitis, J. Clin. Invest. 116 (2006) 447–455.

[113] G. Matarese, P.B. Carrieri, A. La Cava, F. Perna, V. Sanna, V. De Rosa, D. Aufiero, S. Fontana, S. Zappacosta, Leptin increase in multiple sclerosis associates with reduced number of CD4+CD25+ regulatory T cells, Proc. Natl. Acad. Sci. USA 102 (2005) 5150–5155.

[114] M. Barbier, C. Cherbut, A.C. Aubé, H.M. Blottière, J.P. Galmiche, Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats, Gut 43 (1998) 783–790.

[115] B. Siegmund, H.A. Lehr, G. Fantuzzi, Leptin: a pivotal mediator of intestinal inflammation in mice, Gastroenterology 122 (2002) 2011–2025.

[116] N. Busso, A. So, V. Chobaz-Peclat, C. Morard, E. Martinez-Soria, D. Talabot- Ayer, C. Gabay, Leptin signaling deficiency impairs humoral and cellular immune responses and attenuates experimental arthritis, J. Immunol. 168 (2002) 875–882.

[117] M. Otero, J.J. Gomez Reino, O. Gualillo, Synergistic induction of nitric oxide synthase type II: in vitro effect of leptin and interferon-c in human chondrocytes and ATDC5 chondrogenic cells, Arthritis Rheum. 48 (2003) 404–409.

[118] M. Otero, R. Lago, F. Lago, J.J. Reino, O. Gualillo, Signalling pathway involved in nitric oxide synthase type II activation in chondrocytes: synergistic effect of leptin with interleukin-1, Arthritis Res. Ther. 7 (2005) 581–591.

[119] É. Toussirot, F. Michel, D. Binda, G. Dumoulin, The role of leptin in the pathophysiology of rheumatoid arthritis, Life Sci. 140 (2015) 29–36.

[120] C. Procaccini, V. Pucino, C.S. Mantzoros, G. Matarese, Metabolism 64 (2015) 92–104.

[121] M. McMahon, B.J. Skaggs, L. Sahakian, J. Grossman, J. FitzGerald, N. Ragavendra, C. Charles-Schoeman, M. Chernishof, A. Gorn, J.L. Witztum, W. K. Wong, M. Weisman, D.J. Wallace, A. La Cava, B.H. Hahn, High plasma leptin levels confer increased risk of atherosclerosis in women with systemic lupus erythematosus, and are associated with inflammatory oxidised lipids, Ann. Rheum. Dis. 70 (2011) 1619–1624.

[122] B.H. Hahn, E.V. Lourenço, M. McMahon, B. Skaggs, E. Le, M. Anderson, N. Iikuni, C.K. Lai, A. La Cava, Pro-inflammatory high-density lipoproteins and

58 A. La Cava / Cytokine 98 (2017) 51–58

atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin, Lupus 19 (2010) 913–917.

[123] E.V. Lourenço, A. Liu, G. Matarese, A. La Cava, Leptin promotes systemic lupus erythematosus by increasing autoantibody production and inhibiting immune regulation, Proc. Natl. Acad. Sci. USA 113 (2016) 10637–10642.

[124] G. Amarilyo, N. Iikuni, A. Liu, G. Matarese, A. La Cava, Leptin enhances availability of apoptotic cell-derived self-antigen in systemic lupus erythematosus, PLoS ONE 9 (2014) e112826.

[125] Y. Liu, Y. Yu, G. Matarese, A. La Cava, Cutting edge: fasting-induced hypoleptinemia expands functional regulatory T cells in systemic lupus erythematosus, J. Immunol. 188 (2012) 2070–2073.

[126] A.A. Cerman, S. Bozkurt, A. Sav, A. Tulunay, M.O. Elbas�i, T. Ergun, Serum leptin levels, skin leptin and leptin receptor expression in psoriasis, Br. J. Dermatol. 159 (2008) 820–826.

[127] H. Takahashi, H. Tsuji, I. Takahashi, Y. Hashimoto, A. Ishida-Yamamoto, H. Iizuka, Plasma adiponectin and leptin levels in Japanese patients with psoriasis, Br. J. Dermatol. 159 (2008) 1207–1208.

[128] G.S. Feng, S. Zhang, Z.Y. Zhang, PTP1B as a drug target: recent developments in PTP1B inhibitor discovery, Drug Discov. Today 12 (2007) 373–381.

[129] G.S. Feng, Shp2 as a therapeutic target for leptin resistance and obesity, Expert Opin. Ther. Targets 10 (2006) 135–142.